Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tricida, Inc.,  (Nasdaq: TCDA) today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase 840,000 additional shares of common stock for total gross proceeds of approximately $231.8 million, before deducting underwriting discounts and commissions and other offering expenses payable by Tricida.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Needham & Company, LLC acted as co-manager.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission and became effective under the Securities Act of 1933, as amended, on April 3, 2019. The offering was made only by means of a prospectus, copies of which may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, or by emailing; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, or facsimile: 631-254-7140.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD) by binding and removing acid from the gastrointestinal tract.



Jackie Cossmon, IRC
Tricida, Inc.
Vice President of Investor Relations and Communications


Source: Tricida, Inc.

Back to news